Description: Targovax ASA, a clinical stage immuno-oncology company, engages in the development of immune activators to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102, which is in Phase I/II clinical trials for the treatment of mesothelioma, melanoma, and colorectal cancer. The company is also developing neoantigen vaccines targeting mutant KRAS cancers. In addition, it is developing ONCOS-211 for next generation ONCOS viruses. The company has collaboration agreements with Cancer Research Institute and Ludwig Cancer Research to develop ONCOS-102 for colorectal cancer with peritoneal carcinomatosis; Valo Therapeutics to develop mutant RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Papyrus Therapeutics to develop novel ONCOS viruses with Receptor Tyrosine Kinase inhibitor functionality. Targovax ASA was incorporated in 2010 and is based in Lysaker, Norway.
Home Page: www.targovax.com
Vollsveien 19
Lysaker,
1366
Norway
Phone:
47 21 39 88 10
Officers
| Name | Title |
|---|---|
| Dr. Erik Digman Wiklund | Chief Exec. Officer |
| Dr. Victor Levitsky M.D., Ph.D. | Chief Scientific Officer |
| Dr. Lone Ottesen M.D., Ph.D. | Chief Medical Officer |
| Mr. Ola Melin | Head of Manufacturing |
| Ms. Ingunn Munch Lindvig | VP of Regulatory Affairs |
| Dr. Lubor Gaal Ph.D. | Chief Financial Officer |
| Mr. Jon Amund Eriksen M.Sc., MSc | Special Advisor |
| Prof. Gustav Gaudernack Ph.D. | Chief Scientific Adviser |
| Dr. Peter Skorpil Ph.D. | VP of Bus. Devel. |
Exchange: OL
Country: NO
Currency: Norwegian Krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6059 |
| Price-to-Sales TTM: | 1925.3989 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 19 |